The 62 references in paper П. Лагута С., П. Лагута С. (2014) “ПРИМЕНЕНИЕ АЦЕТИЛСАЛИЦИЛОВОЙ КИСЛОТЫ У КАРДИОЛОГИЧЕСКИХ БОЛЬНЫХ: СУЩЕСТВУЮЩИЕ ПРОБЛЕМЫ И НОВЫЕ ПОКАЗАНИЯ” / spz:neicon:aterotromboz:y:2014:i:1:p:5-21

1
Campbell CL, Smyth S. et. al. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA, 2007;297:2018–24.
(check this in PDF content)
2
Morita I., Schindler M. et al. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and –2. J. Biol. Chem., 1995;270:10902–8.
(check this in PDF content)
3
Smith WL. Prostanoid biosynthesis and the mechanism of action. Am. J. Physiol., 1992;263; F118-F191.
(check this in PDF content)
4
Hinz B, Brune K. Cyclooxygenase-2–10 years later. JPET, 2002;300:367–375.
(check this in PDF content)
5
Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Ann. Rev. Pharmacol. Toxicol., 1998;38:97–120.
(check this in PDF content)
6
Patrono C. et al. Platelet-Active Drugs: The Relationships among dose, effectiveness, and side effects. The Seventh ACCP Conference of Antithrombotic and Thrombolytic Therapy 2004. Chest, 2004;126:234s-264s.
(check this in PDF content)
7
Eikelboom JW, Hirsh J. et al. Antiplatelet Drugs. Antithrombotic therapy and prevention of thrombosis, 9th ACCP Evidence – based Clinical Practice Guidelines. Chest, 2012;141 (2):89s-119s.
(check this in PDF content)
8
Clarke RJ, Mayo G. et al. Suppression of thromboxane A2 but not systemic prostacyclin by controlled-release aspirin. N. Engl. J. Med., 1991;325:1137–41.
(check this in PDF content)
9
McAdam BF, Catella-Lawson F. et al. Systemic biosynthesis of prostacyclin by cyclooxygenase-2: the human pharmacology of a selective inhibitor of cyclooxygenase-2. Proc. Natl. Acad. Sci. USA, 1999;96:272–77.
(check this in PDF content)
10
Reilly IAG, FitzGerald GA. Aspirin in cardiovascular disease. 1988;35:154–76.
(check this in PDF content)
11
Kearney P, Baigent C, Godwin J. et al. Do selective cyclo-oxygenase-2 inhibitors and traditional nonsteroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomized trials. Br. Med. J., 2006;332:1302–8.
(check this in PDF content)
12
McConnel H. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J., 2002;324:71–86.
(check this in PDF content)
13
Pedersen AK, FitzGeralg GA. Dose-related kinetics of aspirin: presystemic acetylation of platelet cyclooxygenase. N. Engl. J. Med., 1984;311:1206–11.
(check this in PDF content)
14
Juul-Moller S, Edvardsson N, Jahnmatz B. et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients in patients with stable chronic angina pectoris. Lancet, 1992;340: 421–5.
(check this in PDF content)
15
Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISK Group. Lancet, 1990;336:827–30.
(check this in PDF content)
16
The SALT Collaborative Group. Swedish Aspirin Low Dose Trial (SALT) of 75 mg aspirin in secondary prophylaxis after cerebrovascular ischaemic events. Lancet, 1991;338:1345–9.
(check this in PDF content)
17
Lindblad B, Persson NH. et al. Does low dose acetylsalicylic acid prevent stroke after carotid surgery? Stroke, 1993;24 (8):1125–8.
(check this in PDF content)
18
The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N. Engl. J. Med., 1991;325:1261–66.
(check this in PDF content)
19
Taylor DW, Barnett HJM. et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: randomised controlled trial. Lancet, 1999;353:2179–83.
(check this in PDF content)
20
Mangano D. T. Aspirin and mortality from coronary bypass surgery. N. Engl. J. Med., 2002;347:1309–17.
(check this in PDF content)
21
Vandvik O, Lincoff AM. et al. Primary and secondary prevention of cardiovascular disease. Antithrombotic therapy and prevention of thrombosis, 9th ACCP Evidence – based Clinical Practice Guidelines. Chest, 2012;141 (2):637s-668s.
(check this in PDF content)
22
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST segment elevation. The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST segment elevation of the European Society of Cardiology. Eur. Heart J., 2011;32:2999–3054.
(check this in PDF content)
23
OGara PT, Kushner FG, Ascheim DD. et al. 2013 ACCF/AHA Guideline for the management of patients ST elevation myocardial infarction. Journal of the American College of Cardiology, 2013;61:78–140.
(check this in PDF content)
24
Antithrombotic Trialists (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet, 2009;373:1849–60.
(check this in PDF content)
25
Final report on the aspirin component of the ongoing Physicians’ Health Study. Steering Commitee of the Physicians’ Health Study Research Group. N. Engl. J. Med., 1989;321:129–35.
(check this in PDF content)
26
Peto R, Gray R, Collins R. et al. Randomized trial of prophylactic daily aspirin in British male doctors. Br. Med. J., 1988;296:313–6.
(check this in PDF content)
27
Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council’s General Practice Research Framework. Lancet, 1998;351:233–41.
(check this in PDF content)
28
Hansson L, Zanchetti A, Carruthers S. G. et al. Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: principal results of Hypertension Optimal Treatment (HOT) randomized trial. Lancet, 1988;351:1766–62.
(check this in PDF content)
29
Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet, 2001;357:89–95.
(check this in PDF content)
30
Ridker P, Cook N, Min Lee L. et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N. Engl. J. Med., 2005;352.
(check this in PDF content)
31
Seshasai SRK, Wijesuriya S, Sivakumaran R. et al. Effect of aspirin on vascular and non-vascular outcomes: meta-analysis of randomised controlled trials. Arch Intern Med, 2012;172 (3):209–16.
(check this in PDF content)
32
Ogawa H, Nakayama M, Morimoto T. et al. Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Lowdose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA, 2008;300 (18):2134–41.
(check this in PDF content)
33
Belch J, MacCuish A, Campbell et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomized placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. Br. Med. J., 2008;337: a1840.
(check this in PDF content)
34
Fowkes FG, Price JF, Stewart MC. et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA, 2010;303 (9):841–8.
(check this in PDF content)
35
Rothwell PM, Price JF et al. Short-term effects of daily aspirin on cancer incidence, mortality, and nonvascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet, 2012;379:1602–12.
(check this in PDF content)
36
Rothwell PM, Fowkes FGR et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patients data from randomised trials. Lancet, 2011;377:31–41.
(check this in PDF content)
37
Jacobs EJ, Newton CC, et al. Daily aspirin use and cancer mortality in large US cohort. J. Natl. Cancer Inst., 2012;104:10p.
(check this in PDF content)
38
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur. Heart J., 2012;33:1635–1701.
(check this in PDF content)
39
Centers for Disease Control and Prevention. Nationa; Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2007, Atlanta, US Department of Health and Human Services, Centers for Disease Control and Prevention., 2008.
(check this in PDF content)
40
Buse JB, Ginsberg HN, Bakris GL. et al. Primary prevention of cardiovascular Disease in people with diabetes mellitus: a scientific statement from American Heart Association and The American Diabetes Association. Circulation, 2007;115:114–26.
(check this in PDF content)
41
Pignone M, Alberts MJ, Colwell JA. Aspirin for Primary Prevention of Cardiovascular Events in people with diabetes. Circulation, 2010;121:2694–2701.
(check this in PDF content)
42
Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 14. ETDRS Investigators. JAMA, 1992;268:1292–1300.
(check this in PDF content)
43
Pearson TA, Blair SN. et. al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patient without Coronary or other Atherosclerotic Vascular Diseases. Circulation, 2002;106:388–91.
(check this in PDF content)
44
Well J, Colin-Jones D. et al. Prophylactic aspirin and risk of peptic ulcer bleeding. Br. Med. J., 1995;310:827–30.
(check this in PDF content)
45
Garcia Rodriguez LA, Cattaruzzi C. et al. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal and anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch. Intern Med, 1998;158:33–9.
(check this in PDF content)
46
Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Am. J. Gastroent., 1998;93:2037–46.
(check this in PDF content)
47
Chan FK, Chung SC. et al. Preventing recurrent upper gastrointestinal bleeding in patient with Helicobacter pylori infection who are taken low dose aspirin or naproxen. N. Engl. J. Med., 2001;344:967–73.
(check this in PDF content)
48
Lai KC, Lam SK. et. al Lansoprazole for the prevention of recurrences of ulcer complications from long term low dose aspirin use. N. Engl. J. Med., 2002;346:2033–8.
(check this in PDF content)
49
McKee SA, Sane DS, Deliargyris EN. Aspirin Resistance in Cardiovascular Disease: A Review of Prevalence, Mechanisms, and Clinical Significance. Thromb Haemost., 2002;88:711–5.
(check this in PDF content)
50
Patrono C.: Aspirin resistance. definition, mechanism and clinical read-outs. J. Thromb Haemost, 2003;1:1710–13.
(check this in PDF content)
51
Snoep JD, Hovens MM. et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch. Intern Med, 2007;167:1593–9.
(check this in PDF content)
52
Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation, 2002;105:1650-5.
(check this in PDF content)
53
Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. JACC, 2003;41:961-5.
(check this in PDF content)
54
Lordkipanidze M, Pharand C, Schampaer E. et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patient with stable coronary artery disease. Eur Hear J, 2007;28:1702–8.
(check this in PDF content)
55
Kuliczkowski W, Witkowski A. et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drug resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur. Heart J., 2009;30:426–35.
(check this in PDF content)
56
Naess IA, Christiansen SC. et al. Incidence and mortality of venous thrombosis: a population based study. J. Thromb. Haemost., 2007;5:692–9.
(check this in PDF content)
57
Kearon C., Akl EA. et al. Antithrombotic therapy for VTE disease. Antithrombotic therapy and prevention of thrombosis, 9th ACCP Evidence – based Clinical Practice Guidelines. Chest, 2012;141 (2):419s-494s.
(check this in PDF content)
58
Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet, 2000;355:1295–1302.
(check this in PDF content)
59
Grady D, Wenger NK, Herrington D. et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med, 2000;132:689–96.
(check this in PDF content)
60
The ESPS 2 Group. European Stroke Prevention Study 2. Efficacy and safety data. Secondary endpoints. J Neurol Sci., 1997;151: S27-S37.
(check this in PDF content)
61
Becattini C, Agnelli G, Schenone A. et al. Aspirin for preventing the recurrence of venous thromboembolism. N. Engl. J. Med, 2012;366:1959–67.
(check this in PDF content)
62
Brighton TA, Eikelboom JW et al. Low-dose aspirin for preventing the recurrent venous thromboembolism. N. Engl. J. Med, 2012; Nov 4. NEJM.org.
(check this in PDF content)